| Literature DB >> 28041669 |
Mary T Caserta1, Hongmei Yang2, Steven R Gill3, Jeanne Holden-Wiltse2, Gloria Pryhuber4.
Abstract
OBJECTIVE: To determine the burden of viral respiratory infections in preterm infants both during and subsequent to neonatal intensive care unit (NICU) hospitalization and to compare this with term infants living in the community. STUDYEntities:
Keywords: Neonatal Intensive Care Unit; prematurity; viral respiratory infection
Mesh:
Year: 2016 PMID: 28041669 PMCID: PMC5328856 DOI: 10.1016/j.jpeds.2016.11.077
Source DB: PubMed Journal: J Pediatr ISSN: 0022-3476 Impact factor: 4.406
Primers and probes used in TAC detection system
| Pathogens | Forward | Final conc. | Reverse | Final conc. | Key | Probe | Final conc. | Authors | Year |
|---|---|---|---|---|---|---|---|---|---|
| Influenza A | GAC CRA TCC TGT CAC CTC TGA C | 800 nM | AGG GCA TTY TGG ACA AAK CGT CTA | 800 nM | # | FAM-TGC AGT CCT CGC TCA CTG GGC ACG-BHQ1 | 200 nM | CDC | 2009 |
| Influenza B | TCC TCA AYT CAC TCT TCG AGC G | 800 nM | CGG TGC TCT TGA CCA AAT TGG | 800 nM | FAM-CCA ATT CGA GCA GCT GAA ACT GCG GTG-BHQ1 | 200 nM | CDC | 2009 | |
| RSV | GGC AAA TAT GGA AAC ATA CGT GAA | 500 nM | TCT TTT TCT AGG ACA TTG TAY TGA ACA G | 250 nM | FAM-CTG TGT ATG TGG AGC CTT CGT GAA GCT-BHQ1 | 50 nM | Fry et al | 2010 | |
| PIV 1 | ACA AGT TGT CAA YGT CTT AAT TCR TAT | 500 nM | TCG GCA CCT AAG TAR TTY TGA GTT | 500 nM | FAM-ATA GGC CAA AGA “T”TG TTG TCG AGA CTA TTC CAA | 50 nM | Weinberg et al | 2013 | |
| PIV 2 | GCA TTT CCA ATC TAC AGG ACT ATG A | 750 nM | ACC TCC TGG TAT AGC AGT GAC TGA AC | 750 nM | FAM-CCA TTT ACC “T”AA GTG ATG GAA TCA ATC GCA AA | 50 nM | Kodani et al | 2011 | |
| PIV 3 | TGG YTC AAT CTC AAC AAC AAG ATT TAA G | 750 nM | TAC CCG AGA AAT ATT ATT TTG CC | 500 nM | FAM-CCC RTC TG“T” TGG ACC AGG GAT ATA CTA CAA A | 200 nM | Kodani et al | 2011 | |
| hRV | CY˟ | 1000 nM | GAA ACA CGG ACA CCC AAA GTA | 1000 nM | FAM-TCC TCC GGC CCC TGA ATG YGG C-BHQ1 | 100 nM | Harvey et al | 2016 | |
| EV | GGT GGC TGC GTT GGC | 1000 nM | GAA ACA CGG ACA CCC AAA GTA | 1000 nM | FAM-TCC TCC GGC CCC TGA ATG YGG C-BHQ1 | 100 nM | Harvey et al | 2016 | |
| ADV | GCC CCA GTG GTC TTA CAT GCA CAT C | 500 nM | GCC ACG GTG GGG TTT CTA AAC TT | 500 nM | FAM-TGC ACC AGA CCC GGG CTC AGG TAC TCC GA-BHQ1 | 100 nM | Heim et al | 2003 | |
| Coronavirus 1 (229E) | CAG TCA AAT GGG CTG ATG CA | 750 nM | AAA GGG CTA TAA AGA GAA TAA GGT ATT CT | 500 nM | FAM-CCC TGA CGA CCA CGT TGT GGT TCA-BHQ1 | 50 nM | Dare et al | 2007 | |
| Coronavirus 2 (NL63) | GAC CAA AGC ACT GAA TAA CAT TTT CC | 250 nM | ACC TAA TAA GCC TCT TTC TCA ACC C | 250 nM | FAM-AAC ACG CT”T” CCA ACG AGG TTT CTT CAA CTG AG | 50 nM | Dare et al | 2007 | |
| Coronavirus 3 (OC43) | CGA TGA GGC TAT TCC GAC TAG GT | 500 nM | CCT TCC TGA GCC TTC AAT ATA GTA ACC | 750 nM | FAM-TCC GCC TGG CAC GGT ACT CCC T-BHQ1 | 50 nM | Dare et al | 2007 | |
| Coronavirus 4 (HKU1) | CCT TGC GAA TGA ATG TGC T | 100 nM | TTG CAT CAC CAC TGC TAG TAC CAC | 750 nM | FAM-TGT GTG GCG GTT GCT ATT ATG TTA AGC CTG-BHQ1 | 50 nM | Dare et al | 2007 | |
| RNP3 | CCA AGT GTG AGG GCT GAA AAG | 600 nM | TGT TGT GGC TGA TGA ACT ATA AAA GG | 600 nM | FAM-CC CCA GTC TCT GTC AGC ACT CCC TTC-BHQ1 | 200 nM | Weinberg et al | 2013 | |
| GAPDH | Life Technologies | ||||||||
| hMPV | CAA GTG TGA CAT TGC TGA YCT RAA | 600 nM | ACT GCC GCA CAA CAT TTA GRA A | 600 nM | FAM-TGG CYG TYA GCT TCA GTC AAT TCA ACA GA-BHQ1 | 100 nM | Kodani et al | 2011 | |
| hBoV | TGC AGA CAA CGC YTA GTT GTT T | 500 nM | CTG TCC CGC CCA AGA TAC A | 500 nM | FAM-CCA GGA TTG GGT GGA ACC TGC AAA-BHQ1 | 100 nM | Lu et al | 2006 | |
| hPeV | GTA ACA SWW GCC TCT GGG SCC AAA AG | 400 nM | GGC CCC WGR TCA GAT CCA YAG T | 400 nM | FAM-CCT RYG GGT ACC TYC WGG GCA TCC TTC-BHQ1 | 200 nM | Nix et al | 2008 | |
| ATG GCG GGA ACA TCA ATG A | 300 nM | ACG CAT AGG AGG GAA ATG GTT | 300 nM | FAM-CGG TAA TTG GGA TCC AT-MGB | 100 nM | Meyler et a. | 2012 | ||
| ACG CAA TCT AGC AGA TGA AGC A | 500 nM | TCG TGC GTT TTA ATT CCA GCT | 500 nM | FAM-TGC CGA AAA CGC TTG ATA CAG GGA G-BHQ1 | 100 nM | Carvalho et al | 2007 | ||
| TTT GGT AGC TGG TTA CGG GAA T | 500 nM | GGT CGG CAC GAA TTT CAT ATA AG | 500 nM | FAM-TGT ACC AGA GCA CCC CAG AAG GGC T- BHQ1 | 100 nM | Winchell et al | 2008 | ||
| GGG CTA TAA AGG CGT TGC TTT | 500 nM | AGA CTT TGT TCC AGT AGC TGT TGC T | 500 nM | FAM-CC TTG CCA ACA GAC GCT GGC G-BHQ1 | 100 nM | Mitchell et al | 2009 | ||
| TCA CTA AAC CGG GTA TTT TCT AAC AA | 300 nM | TTG GCA TAT ATT GCG ATA GTG CTT | 300 nM | FAM-CTA CCA ATA ATT TTA ATA TCT GTC GGT ATG-BHQ1 | 200 nM | Ferandon et al | 2011 | ||
| Ureaplasma | CATACAGAAGGTGCTGGTGG | 500 nM | CTTAGGATTTAAGTGGTGACATAC | 500 nM | FAM-AGC TTC TAC AAA CCC AAC TAT TCC-BHQ1 | 400 nM | Xiao et al | 2010 | |
| CAA GGC CGA ACG CTT CAT | 300 nM | GAG TTC TGG TAG GTG TGA GCG TAA | 300 nM | FAM-CAG TCG GCC TTG CGT GAG TGG G-BHQ1 | 300 nM | Tatti et al | 2008 | ||
| CGC CAG CTC GTA CTT C | 700 nM | GAT ACG GCC GGC ATT | 700 nM | FAM-AAT ACG TCG ACA CTT ATG GCG A-BHQ1 | 300 nM | Tatti et al | 2008 | ||
ADV, adenovirus; B pertussis, Bordetella pertussis; C pneumoniae, Chlamydophila pneumonia; conc. concentration; EV, enterovirus; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; H influenzae, Haemophilus influenzae; hBoV, human bocavirus; hMPV, human metapneumovirus; hPeV, human parechovirus; M hominis, Mycoplasma hominis; M pneumoniae, Mycoplasma pneumoniae; PIV, parainfluenza virus; RNP3, Human RNAse P; S pneumoniae, Streptococcus pneumonia.
Underlining and boldface indicate a locked nucleic acid (Exiqon, Woburn, Massachusetts). Quotation marks around a letter indicate an internal quencher.
5′FAM 3′BHQ1.
Internally labeled probes:5′FAM “T” = BHQ1-dT 3′ = phosphorylated.
Y = mix of C and T (pyrimidine) nucleosides, similar to “P” as listed in Harvey et al. P is a universal base; (P) = dP-CE (pyrimidine derivative), designed to base pair with either A or G.
5′FAM 3′MGB.
Characteristics of the study population
| PT | Term | Total | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | ||
| Cohorts | ||||||
| Term | . | . | 96 | 100.00 | 96 | |
| PT 23-25 6/7 wk | 21 | 22.6 | . | . | 21 | |
| PT 26-27 6/7 wk | 11 | 11.8 | . | . | 11 | |
| PT 28-29 6/7 wk | 10 | 10.8 | . | . | 10 | |
| PT 30-31 6/7 wk | 21 | 22.6 | . | . | 21 | |
| PT 32-33 6/7 wk | 14 | 15.1 | . | . | 14 | |
| PT 34-35 6/7 wk | 16 | 17.2 | . | . | 16 | |
| Delivery mode | ||||||
| Cesarean | 67 | 72.0 | 41 | 42.7 | 108 | <.001 |
| Vaginal | 26 | 28.0 | 55 | 57.3 | 81 | |
| Multiples | ||||||
| Singles | 54 | 58.1 | 94 | 97.9 | 148 | <.001 |
| Multiples | 39 | 41.9 | 2 | 2.1 | 41 | |
| Sex | ||||||
| Female | 46 | 49.5 | 37 | 38.5 | 83 | .13 |
| Male | 47 | 50.5 | 59 | 61.5 | 106 | |
| Race | ||||||
| White | 50 | 53.8 | 54 | 56.3 | 104 | .10 |
| Black/AA | 33 | 35.5 | 23 | 24.0 | 56 | |
| More than 1 race/others/unknown or not reported | 10 | 10.8 | 19 | 19.8 | 29 | |
| Ethnicity | ||||||
| Hispanic/Latino | 10 | 10.8 | 19 | 19.8 | 29 | .05 |
| Not Hispanic/Latino | 82 | 88.2 | 72 | 75.0 | 154 | |
| Unknown or not stated | 1 | 1.1 | 5 | 5.2 | 6 | |
AA, African American; PT, preterm.
Figure 1Sampling seasons by cohort and location. PT, preterm.
Characteristics of infants who acquired a viral respiratory infection during the NICU hospitalization
| Gestational ages (wk) at birth | Gestational ages (wk) at infection | Age (d) at infection | Sex | Race | Virus |
|---|---|---|---|---|---|
| 266/7 | 392/7 | 88 | Female | Black/AA | RSV |
| 236/7 | 266/7 | 22 | Female | Black/AA | Rhinovirus |
| 245/7 | 396/7 | 107 | Female | Black/AA | Coronavirus 4 |
| 231/7 | 373/7 | 101 | Male | More than 1 race/others/unknown or not reported | Influenza B |
Figure 2A, Kaplan-Meier curve estimators and log-rank test for preterm NICU samples compared with term home samples, B, Preterm home samples compared with term home samples.
Total number of viral respiratory infections in the first 4 months after hospital discharge by cohort
| Total number of positive infection | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | |||||||
| n | % | n | % | n | % | n | % | n | % | n | |
| PT: home | 27 | 35.5 | 25 | 32.9 | 17 | 22.4 | 7 | 9.2 | . | . | 76 |
| Term: home | 22 | 29.0 | 32 | 42.1 | 17 | 22.4 | 3 | 4.0 | 2 | 2.6 | 76 |
| Total | 49 | 32.2 | 57 | 37.5 | 34 | 22.4 | 10 | 6.6 | 2 | 1.3 | 152 |
PT, preterm.
P value = .39 for test of same rate of ever infection between 2 cohorts at home.
Full-term cohort, n = 76 because of study attrition.
Preterm cohort, N = 76 due to death, transfer to outside hospital, continuing hospitalization.
Viruses causing infection after hospital discharge
| PT | Term | Total | |
|---|---|---|---|
| n | n | n | |
| Adenovirus | 2 | 2 | 4 |
| Bocavirus | 1 | 2 | 3 |
| Coronavirus 1 | 0 | 1 | 1 |
| Coronavirus 2 | 7 | 2 | 9 |
| Coronavirus 3 | 2 | 1 | 3 |
| Coronavirus 4 | 5 | 0 | 5 |
| Enterovirus | 8 | 4 | 12 |
| Parainfluenza 3 | 2 | 1 | 3 |
| Parechovirus | 1 | 0 | 1 |
| RSV | 3 | 7 | 10 |
| Rhinovirus | 49 | 62 | 111 |
| Metapneumovirus | 0 | 1 | 1 |
Number of illness visits in first 4 months after hospital discharge by cohort
| Total number of illness visits | Total | ||||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | |||||
| n | % | n | % | n | % | n | |
| PT | 65 | 85.5 | 10 | 13.2 | 1 | 1.3 | 76 |
| Term | 63 | 82.9 | 11 | 14.5 | 2 | 2.6 | 76 |
| Total | 128 | 84.2 | 21 | 13.8 | 3 | 2.0 | 152 |
P value = .66 for test of same rate of ever sick visit between 2 cohorts at home.
Full-term cohort, N = 76 because of study attrition.
PT cohort, N = 76 because of o death, transfer to outside hospital, continuing hospitalization.
Hazard ratio estimates from the intensity model of days to virus infection in the first 4 months after hospital discharge
| Descriptions | Hazard ratio | Lower | Upper | |
|---|---|---|---|---|
| Corrected gestational age | 0.582 | 0.535 | 0.632 | <.0001 |
| Multiples vs singles | 0.368 | 0.246 | 0.549 | <.0001 |
| Female vs male | 0.616 | 0.431 | 0.880 | .036 |
| Black/AA vs White | 0.522 | 0.344 | 0.792 | .034 |